McLoughlin Margaret
SEC insider (Form 3/4/5 filer). CIK 0001770823. Director at Quince Therapeutics, Inc. (QNCX). 3 reported Form 4/5 transactions since Sep 2024; latest on Jan 2, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies McLoughlin Margaret has filed insider reports for
- Quince Therapeutics, Inc. (QNCX): Director
McLoughlin Margaret
CIK: 0001770823
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Quince Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jan 2, 2026QNCX
Quince Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
19.5K shares- - Jun 4, 2025QNCX
Quince Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
27K shares- - Jan 2, 2025QNCX
Quince Therapeutics, Inc.
AwardDirectDirector Stock Option (right to buy)
31.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | QNCX Quince Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 19,547 | - | - | Direct |
| Jun 4, 2025 | QNCX Quince Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 27,000 | - | - | Direct |
| Jan 2, 2025 | QNCX Quince Therapeutics, Inc. | Award Director Stock Option (right to buy) | 31,613 | - | - | Direct |
1-3 of 3 transactions